[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585257":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":27,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":58,"collaborators":13,"id":60,"slug":13,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":13,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":13,"enrollmentInfo":68,"targetDuration":13,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":13,"overallStatus":46,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Shandong First Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"To evaluate the efficacy after CM336 treatment","Proportion of subjects in sustained complete remission","Up to 52 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","This study will set up two cohorts, Cohort 1: Patients with pemphigus, and plan to enroll approximately 20 adults with pemphigus; and Cohort 2: patients with bullous pemphigoid, and plan to enroll approximately 10 adults with bullous pemphigoid. Cohort 1 is divided into Part 1 and Part 2: Part 1 is planned to enroll approximately 10 subjects with pemphigus who had an inadequate response to prior corticosteroid therapy or whose disease uncontrolled despite high-dose corticosteroids. Part 2 is planned to enroll approximately 10 subjects with pemphigus who had an inadequate response to anti-CD20 monoclonal antibody therapy.",[22],{"label":23,"type":24,"description":13,"interventionNames":25},"Intervention(CM336)","EXPERIMENTAL",[26],"Biological: CM336 Injection",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":13},"BIOLOGICAL","CM336 Injection","subcutaneous CM336 administration",[23],[34],{"name":35,"affiliation":36,"role":37},"Furen Zhang","Dermatology Hospital affiliated to Shandong First Medical University","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":13,"email":42},"CONTACT","15854179852","splcsy@126.com",[44],{"facility":45,"status":46,"city":47,"state":13,"zip":13,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Dermatology Hospital Affiliated to Shandong First Medical University","RECRUITING","Jinan","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.99722,36.66833,{"lat":54,"lon":53},[57],{"name":35,"role":40,"phone":41,"phoneExt":13,"email":13},{"type":59,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100585257",false,"NCT06900010","A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease","An Open-label, PhaseⅡ Study to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease","Inclusion Criteria:\n\n* 1\\. Confirmed diagnosis of autoimmune bullous disease；\n* 2\\. Age ≥18 years, regardless of gender；\n* 3\\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.\n\nExclusion Criteria:\n\n* 1\\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation；\n* 2\\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；\n* 3\\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；\n* 4\\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.","ALL","18 Years",{"count":69,"type":70},30,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease",[76],"Autoimmune Bullous Disease","2026-03-31",{"date":79,"type":80},"2026-04-06","ACTUAL",{"date":82,"type":80},"2025-04-22",{"date":84,"type":70},"2028-01-01",{"name":5,"class":6},1]